» Articles » PMID: 25092300

Protective Hinge in Insulin Opens to Enable Its Receptor Engagement

Abstract

Insulin provides a classical model of a globular protein, yet how the hormone changes conformation to engage its receptor has long been enigmatic. Interest has focused on the C-terminal B-chain segment, critical for protective self-assembly in β cells and receptor binding at target tissues. Insight may be obtained from truncated "microreceptors" that reconstitute the primary hormone-binding site (α-subunit domains L1 and αCT). We demonstrate that, on microreceptor binding, this segment undergoes concerted hinge-like rotation at its B20-B23 β-turn, coupling reorientation of Phe(B24) to a 60° rotation of the B25-B28 β-strand away from the hormone core to lie antiparallel to the receptor's L1-β2 sheet. Opening of this hinge enables conserved nonpolar side chains (Ile(A2), Val(A3), Val(B12), Phe(B24), and Phe(B25)) to engage the receptor. Restraining the hinge by nonstandard mutagenesis preserves native folding but blocks receptor binding, whereas its engineered opening maintains activity at the price of protein instability and nonnative aggregation. Our findings rationalize properties of clinical mutations in the insulin family and provide a previously unidentified foundation for designing therapeutic analogs. We envisage that a switch between free and receptor-bound conformations of insulin evolved as a solution to conflicting structural determinants of biosynthesis and function.

Citing Articles

Stabilization of a protein by a single halogen-based aromatic amplifier.

El Hage K, Dhayalan B, Chen Y, Phillips N, Whittaker J, Carr K Protein Sci. 2025; 34(3):e70064.

PMID: 39969055 PMC: 11837044. DOI: 10.1002/pro.70064.


Synthetic studies of the mutant proinsulin syndrome demonstrate correlation between folding efficiency and age of diabetes onset.

Dhayalan B, Chen Y, Ni C, Weiss M Int J Pept Res Ther. 2025; 31(1).

PMID: 39866851 PMC: 11759498. DOI: 10.1007/s10989-024-10665-z.


A λ-Dynamics Investigation of Insulin and Other A3 Variant Binding Affinities to the Insulin Receptor.

Barron M, Vilseck J J Chem Inf Model. 2024; 64(14):5657-5670.

PMID: 38963805 PMC: 11268370. DOI: 10.1021/acs.jcim.4c00662.


A λ-dynamics investigation of insulin and other A3 variant binding affinities to the insulin receptor.

Barron M, Vilseck J bioRxiv. 2024; .

PMID: 38559010 PMC: 10979964. DOI: 10.1101/2024.03.15.585233.


Clues to the Design of Aggregation-Resistant Insulin from Proline Scanning of Highly Amyloidogenic Peptides Derived from the N-Terminal Segment of the A-Chain.

Pulawski W, Dec R, Dzwolak W Mol Pharm. 2024; 21(4):2025-2033.

PMID: 38525800 PMC: 10988558. DOI: 10.1021/acs.molpharmaceut.4c00077.


References
1.
Williams P, Mynarcik D, Yu G, Whittaker J . Mapping of an NH2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis. J Biol Chem. 1995; 270(7):3012-6. DOI: 10.1074/jbc.270.7.3012. View

2.
De Meyts P, Whittaker J . Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002; 1(10):769-83. DOI: 10.1038/nrd917. View

3.
Menting J, Whittaker J, Margetts M, Whittaker L, Kong G, Smith B . How insulin engages its primary binding site on the insulin receptor. Nature. 2013; 493(7431):241-5. PMC: 3793637. DOI: 10.1038/nature11781. View

4.
Stoy J, Edghill E, Flanagan S, Ye H, Paz V, Pluzhnikov A . Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A. 2007; 104(38):15040-4. PMC: 1986609. DOI: 10.1073/pnas.0707291104. View

5.
Whittaker L, Hao C, Fu W, Whittaker J . High-affinity insulin binding: insulin interacts with two receptor ligand binding sites. Biochemistry. 2008; 47(48):12900-9. PMC: 2819479. DOI: 10.1021/bi801693h. View